A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma.

Project Information

CLINGLIO

Grant agreement ID: 755179

DOI 10.3030/755179

Project closed

EC signature date 27 November 2017

Start date 1 December 2017

End date 31 May 2022

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 6 155 125,00

EU contribution € 6 155 125,00

Coordinated by

LAMINAR PHARMACEUTICALS SA
Spain

Deliverables

Websites, patent fillings, videos etc. (1)

First regulatory approval of final version of study protocol

Approvals required for invitation / enrolment of first subject in at least one clinical centre: Ethic Committee, Competent Authority and National Data Protection Authority). Registration in Primary Registries in the WHO Registry Network (EU Clinical Trials Register (EU-CTR)).

Documents, reports (6)

Protocols and laboratory manual for miRNAS, mRNA expression and RNAseq
Statistical protocols
Report on the status of posting results

Report on the status of posting results in the study registryies including timelines when final posting of results is scheduled after end of funding period To be scheduled for the time of expected results

Sample protocols for liquid biopsy biomarkers
Protocols for protein biomarker determinations

Protocols for protein biomarker determinations (GFAP, mTOR, pAkt, SMS1, SMS2, etc.).

Consititution of the different management bodies

Constitution of the different management bodies

Other (1)

Public Web Site and Project Presentation

Design and maintenance of dedicated project web site with an offering of the typical electronic dissemination facilities

Open Research Data Pilot (1)

SMS1 and SMS2 molecular modelling

(i) determination of SMS1 structure , (ii) determination of SMS2 structure, (iii) determination of SMS1-2OHOA and SMS2-2OHOA interactions, and (iv) determination of the structure and interaction with 2OHOA for specific mutants selected from other experiments in this WP

Demonstrators, pilots, prototypes (1)

Clinical Trial registration number

EudraCT

Publications

Peer reviewed articles (6)

Study of the Interaction of a Novel Semi-Synthetic Peptide with Model Lipid Membranes

Author(s): Lucia Sessa, Simona Concilio, Peter Walde, Tom Robinson, Petra S. Dittrich, Amalia Porta, Barbara Panunzi, Ugo Caruso, Stefano Piotto
Published in: Membranes, Issue 10/10, 2020, Page(s) 294, ISSN 2077-0375
Publisher: Molecular Diversity Preservation International
DOI: 10.3390/membranes10100294

Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues

Author(s): Doralicia Casares, Pablo V. Escribá, Catalina Ana Rosselló
Published in: International Journal of Molecular Sciences, Issue 20/9, 2019, Page(s) 2167, ISSN 1422-0067
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms20092167

The Opposing Contribution of SMS1 and SMS2 to Glioma Progression and Their Value in the Therapeutic Response to 2OHOA

Author(s): Paula Fernández-García, Catalina A. Rosselló, Raquel Rodríguez-Lorca, Roberto Beteta-Göbel, Javier Fernández-Díaz, Victoria Lladó, Xavier Busquets, Pablo V. Escribá
Published in: Cancers, Issue 11/1, 2019, Page(s) 88, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers11010088

The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt

Author(s): Francisca Guardiola-Serrano, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Maitane Ibarguren, David J. López, Silvia Terés, María Alonso-Sande, Mónica Higuera, Manuel Torres, Xavier Busquets, Pablo V. Escribá
Published in: Oncotarget, Issue 10/26, 2019, ISSN 1949-2553
Publisher: Impact Journals
DOI: 10.18632/oncotarget.26824

Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity

Author(s): Wessal Massalha, Mark Markovits, Edward Pichinuk, Yael Feinstein-Rotkopf, Mark Tarshish, Kumudesh Mishra, Victoria Llado, Miguel Weil, Pablo V. Escriba, Or Kakhlon
Published in: Bioscience Reports, Issue 39/1, 2019, Page(s) BSR20181661, ISSN 0144-8463
Publisher: Kluwer Academic Publishers
DOI: 10.1042/bsr20181661

The Implications for Cells of the Lipid Switches Driven by Protein–Membrane Interactions and the Development of Membrane Lipid Therapy

Author(s): Manuel Torres, Catalina Ana Rosselló, Paula Fernández-García, Victoria Lladó, Or Kakhlon, Pablo Vicente Escribá
Published in: International Journal of Molecular Sciences, Issue 21/7, 2020, Page(s) 2322, ISSN 1422-0067
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms21072322

Intellectual Property Rights

Patent (2)

ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS INTENDED FOR USE AS A DRUG

Application/Publication number: EP 09831504
Date: 2009-12-04
Applicant(s): UNIVERSITAT DE LES ILLES BALEARS

USE OF HYDROXYOLEIC ACID AND SIMILAR COMPOUNDS IN THE PRODUCTION OF MEDICAMENTS

Application/Publication number: EP 02783094
Date: 2002-10-09
Applicant(s): UNIVERSITAT DE LES ILLES BALEARS